Xiromed, LLC, the New Jersey-based generic division of Insud Pharmaceuticals, announced today that it has entered into a long-term strategic collaboration with Gland Pharma Ltd, headquartered in Hyderabad, India. The development and commercialization partnership covers a basket of generic injectable products developed by Gland, which will be marketed in the United States by Xiromed. The U.S. Food and Drug Administration (FDA) has granted approval for three of the products covered under the partnership, which will be launched by Xiromed within the current fiscal year. The additional products are filed Abbreviated New Drug Applications (ANDAs) currently under review with the FDA.
Xiromed CEO, Narasimhan Mani commented, “This collaboration brings together the expertise of Xiromed’s seasoned commercial team and Gland’s robust development and commercial manufacturing capabilities. We are excited to enter into this relationship with Gland and look forward to creating long-term value for both companies as we continue to grow the partnership.”
Srinivas Sadu, MD and CEO of Gland Pharma added, “We are happy to collaborate with Xiromed for marketing and distribution of Gland ANDAs in the U.S. market. This partnership further strengthens our commitment towards delivering affordable medications addressing patient needs.”Xiromed, LLC, located in Florham Park, NJ, is the US Generic Pharmaceuticals division of Insud Pharma, S.L., a global pharmaceutical company headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic products for the US market. In addition to its commercial portfolio of generics available in the United States, Xiromed has a robust development pipeline of generic pharmaceutical products, which includes injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/